https://doi.org/10.48047/AFJBS.6.12.2024.4541-4554



African Journal of Biological Sciences

Journal homepage: http://www.afjbs.com



Research Paper

Open Access

ISSN: 2663-2187

A Review of Anaesthesia Drug (Propofol and Remifentanil)

Dr.R.Bharath Kumar¹

Associate Professor

Department: Bio Medical Engineering, Indra Ganesan College of Engineering

Trichy, Manikandam, Tamil Nadu bharathkumarece@igceng.com

Orcid number: 0000-0002-6941-6325, Scopus Id: 57224954809

Dr.M.Bhuvaneswari²

Associate Professor

Department: Electronics and Communication Engineering, Indra Ganesan College of

Engineering

Trichy, Manikandam, Tamil Nadu bhuvanagopi97@gmail.com

Jeya. Thamarai Ezhil³

Assistant Professor

Department: PHYSIOTHERAPY

Shri Indra Ganesan Institute of Medical Science, College of Physiotheraphy

Trichy, Manikandam, Tamil Nadu jeyathamaraiezhil@hotmail.com

Dr.K Uthra Devi⁴

Assistant Professor

Department: Artificial Intelligence and Data Science, Indra Ganesan College of Engineering Trichy, Manikandam, Tamil Nadu

uthra.ud@gmail.com

Mrs.P.Santhana Selvi⁵

Assistant Professor

Department: Electronics and Communication Engineering

Indra Ganesan College of Engineering Trichy, Manikandam, Tamil Nadu selvi.santhana29@gmail.com

Nandhini M⁶

Assistant Professor

Department: Electronics and Communication Engineering
Indra Ganesan College of Engineering
Trichy, Manikandam, Tamil Nadu
smnandhini123@gmail.com

Article History

Volume 6, Issue 12, 2024 Received: June 10, 2024 Accepted: July 5, 2024

doi:

10.48047/AFJBS.6.12.2024.4541-4554

Abstract

It sole responsibility of anesthetized to have knowledge about the physical and chemical characteristics of every drugs and its role. At foremost the cautious standard of drug delivery technique with continual intravenous procedure isvery importance to avoid inadequate dosage level to the patient. Development of the new prototype based regulated method are able to say about dosage level given to the patient, but they are truly depends upon the patient body nature. So it must have an adequate awareness about characteristic of each drug before it is used to the humanbody. At finally we had review and examine the outcome of collective effect of commonly used two drugs Propofol (hypnotic) and Remifentanil (opioid) and its lustiness and reliability during operation.

Keywords: Anesthetized, Intravenous, Propofol, Remifentanil, hypnotic, opioid

I. Introduction

A drug is a substance (with the malformation of food and water) when consumeby the human body, which alter the psychology behavior of human being either physically and /or interpersonally. Daily usage drugs are such as (eg. Alcohol, caffeine and tobacco) or banned type such as (eg. Cannabis, ecstasy, cocaine and heroin) [30]. Mainly drugs are categorized into four main classifications they are

- > Stimulants (eg. Cocaine)
- > Depressants (eg. Alcohol)
- Opium-related pain killer (eg. Heroin)
- ➤ Hallucinogens (eg. LSD)

A drug may be called as an Anesthetic (American English) or Anaesthetic (British English) used to persuade anesthesia – the alternate word, it is a transitory loss of outrage or consciousness.

II. Definition of Anaesthesia

Anesthesia[ăn'îs-thē'zhə] is a complete or partial loss of motion to nudge or pain, caused by a nerve fiber wound or disorder or induce purposely, specifically managing the anesthetic drugs, to give healing therapy. The basic categorizations of Anesthesia are shown in the Fig.1.




Fig.1. Classification of Anesthesia

- ➤ Local Anesthesia: Immobilize a specific location of the human region. The sufferer will be at awake state.
- Regional Anesthesia: It obstruct the pain in an exact location of the human region., eg: arm or leg
- ➤ General Anesthesia: It makes the whole body as immobilize state and make the sufferer in insensible state.





Fig.2.Stages of Anesthesia

The dosages of anesthesia drug are shown in the Fig.2 they are 4 stages, above the fourth stage which may leads the patient to the coma stage [3]. So the main aim to regulate the general anesthesia is too given by a stage of mutable unconsciousness with sufficient analgesia and muscle loosening for operation procedure in such a way that it does not harm the patient's health. The knowledge of safe anesthesia requires, practical talent and sharp consciousness of the patient's condition at all times.

IV. History of Anaesthesia drug

In ancient times the people uses different types of nature based drug such as (opium poppy, Coca leaves, Alcohol, Phlebotomy) for a surgical operation

John Snow (1813 – 1858):Is the father of anaesthesia who had made anaesthesia as a technical term by showing how the patient body accept it and accordingly respond to it. Later on the year 1846 the word Anaesthesia is initiated by Oliver Wendell Holmes. Further it is developed and first successful surgical anesthesia (sulfuric ether) given to the patient and it succefully completed by Mr.William Morton (1819 – 1868) [5]. In the modern era of Anesthesia is developed in 19th century by "Association of Anesthetists of Great Britain and Ireland" formed (1932) founded many types of drugs are shown in the Fig.3 and introduced in surgical operation such as.



There are many drugs are introduced till now most frequently used drugs are (Propofol, Etomidate, Barbiturates similar to methohexital and thiopentone/ thiopental, Remifentanil, Benzodiazepines such as midazolam). From that two major drugs are Propofol and Remifentanil we are going to analyze detail about two drugs in this paper.

V. Propofol

It is an inoculation method of drug used in the patient. Propofol otherwise called as DIPRIVAN[®]. It is chemically chronicle as 2, 6-diisopropylphenol [11]. It is imitative of phenolic anatomy shown in the below Fig.4 compose of oil-in-water mixture. The drug was introduced in the year 1984 and further developed by many young scholastic anesthetists. Finally it has been introduced by Paul F.White in sedation of instinctively ventilated adults in ICU (1993) [26].




Fig.4. Structure of Propofol

It has relaxing and drowsiness properties [5]. Propofol is marginally resolvable in water and made up of white, oil-in-water mixture. The pKa is 11. The octanol/water separation constant for Propofol is 6761:1. It consist of other mixture are Soybean oil (100 mg/mL), glycerol (22.5 mg/mL), egg lecithin (12 mg/mL); and disodium edetate (0.005%); with sodium hydroxide to regulate pH [28].

a. Physical Properties

The basic physical properties of Propofol are given in Table.1 shown below.

Molecular Formula	$C_{12}H_{18}O$
Molecular Weight	178.27g/mol
рН	6 to 8.5
Density	$0.9 \pm 0.1 \text{g/cm}^3$
Boiling Point	$256 \pm 0.0^{\circ} \text{ c at } 760$
	mmHg
Vapour Pressure	0.0 ± 0.5 mm Hg at
	25°C
Enthalpy of	51.3 ± 3.0 kJ / mol
Vaporization	
Volume of	60 L/ kg (for Healthy
distribution	Person)

Table.1. Physical Properties of Propofol

b. Pharmacodynamic Properties

Propofol is narcotic-somniferous drugs which are used during the operation to keep the patient in tranquilizing stage. Constant dosages of Propofol (Diprivan®) intensify the sedation in a drug dosage-dependent manner. The objective of plasma propofol dosage level given to the patient is determined to attain a Ramsay sedation score of 2-5 ranged from 0.25 to 2.0mg/L [11]. The disclosure from propofol sedation is depends upon on the some of the factors are duration

and size of the patient, depth of narcotic given. Propofol object is a dose-dependent which reduces the blood pressure and heart rate. Intramuscular injections of a remedial dose of propofol make hypnosis quickly with minimum stimulation, normally within the 40 sec from the starting stage of infusion.

c. Pharmacokinetic Properties

Propofol is mostly Oily organic compounds expedite speedy diffusion to the blood-brain blockade and a quick start of the deed [5]. The pharmacokinetic effects are specifying by 3 compartmental designs:

- ➤ Rapid start diffusion from blood into tissues
- Fast reallocation and metabolism separation.
- > Slow return from insertion tissues into the arteries

Propofol has a rectilinear pharmacokinetic portrayal. At stable level, the acceptance of propofol is depends upon the biological system and diffusion to peripheral epithelium [4]. It is comprehensively metabolized and discharged in urine (≥88%), mostly as inert metabolites [11]. Different type's aspect like age, sex, weight and already known diseases may be change the pharmacokinetic characteristic of propofol

Female: It represents the high amount of diffusion rate.

Elderly: It reduces the clearance rate and reduces the central compartment volume.

Children: It represents the increase in middle compartment volume and quick concurrence.

d. Admissibility

Propofol has a cardiorespiratory sedative result, which can lead the way to low blood pressure and decrease the pulse rate. In specific, tablet dosages of propofol are related with noticeably momentary low blood pressure. Specific care should be taken while giving propofol dosage to the elderly patient who are physically unsteady or blood disorder. Discomfort on inoculation is usual with propofol when they are managing into external veins [20], but it can be decreased by using the wide range of veins in the lower arm. Hypertriglyceridemia is related with propofol dosage of > 3 days [11]. In Fig 5 shows the response of propofol in the blood level by EEG score




Fig.5. Blood level of Propofol

e. Mechanism of Action

The efforts of Propofol concern a positive attenuation of the self-consciousness purpose of the neurotransmitter gama-aminobutyric acid (GABA) through GABA-A receptors. It reduces the amount of isolation of GABA from its sense-organ, thereby extending the time duration of the GABA operated by opening of chloride channel which result action potential of plasma membrane. The flow processes of GABA receptors are shown below in the Fig.6.




Fig.6. Flow Process of GABA

The Fig.7 is shown below describes the fall of body fluid propofol levels following injection at different time interval to the patient in ICU ward.




Fig.7. Plasma Concentration of Propofol

f. Significance and utilization

Initialization and continues observance of stupor care in elderly an only combines of restfulness and epidural anesthesia of patient depend upon the age factor. They are extubation, manually oxygenated patient by propofol at which can be used without any related drug for sedative.

g. Excessive dosage of drug:

There is no antitoxin of Propofol. If excessive dosage occurs in propofol level it should be stopped at instant. Over dosage may cause the cardiovascular respiratory recession. It should be cure by manual oxygen ventilation. It also requires by lifting up the patient's legs, and raising the arterial liquid rate of flow. It also needs to control persuade liaison and antimuscarinic drug. The Table.2 shows the basic characteristics of propofol.

Table.2. Characteristics of Propofol

	1	
Characteristics	Alkyl phenol is arterial narcotic source. It is used in	
	general anesthesia. It also maintains the dosage	
	level in each case by continuous inoculation.	
Classification	Induction Agents	
Dose	Induction: 2-2.5 mg/kg arterial for elders	
	Induction: 0.125- 0.3 mg/kg arterial for infant	
	Sustentation of numbness:100-200 µg/kg/minute	
	Drowsiness: 40-100 µg/kg/minute	
Time span	Around 5-8min after one time dosage level.	
_	Equilibrize effect is more in continuous infusion.	
Rejection time	Abrupt change from central nervous system (CNS)	
	into lean body section for instantaneous wake up.	
Drug Effects	Central Nervous system, Chorionic villus	
	Sampling, Respiratory	
Contraindications	Soy allergy	
Advantage	Rapid onset, Rapid recovery very widely used	
Disadvantages	Can cause respiratory dejection and slow heartbeat.	

h. Future intuition.

Additional assessment is also required to obtain the knowledge of interaction procedure and risk factor of Propofol related to injection symptoms. Usage of Propofol injection in younger patients has been scrutinize because for long time propofol dosage level of 6% when it has been used < 4mg/kg/ hr dosage level can be changed in future execution.

VI. Remifentanil.

Remifentanil basically come under the fentanyl group of semisynthetic anodyne which are supplement to anaesthesia. It is precise mu-type-sedative sense-organ protagonist which reduces the peripheral nervous system tone, and seed hypoventilation and pain-relieving. Initially it, has been accept bythe United States Food and Drug Administration in 1996[1] and patented by Glaxo Wellcome Inc [9]. It is a stupor pain reliever used during the operation. The visceral motor systems give rise to the trouble-free of post-operative and anesthetic period. It is a dominant in ultra-short acting semisynthetic anodyne drug. It is used for narcotic as well as together with other antibiotic for use in general anesthesia. Generally remifentanil are combined with propofol for increase the dose of narcotic and low dose of drowsy state due to the interactive between two drugs. A brand name is Ultiva (remifentanil hydrochloride). The basic chemical structures of remifentanil are shown below in the Fig.8.

Fig.8. Structure of Remifentanil

Remifentanil free base cocaine is put together with glycine. It is prime proscriptive neurotransmitter in the cerebrospinal nervous system of marsupial [5]. Remifentanil is obtained as a white powder which can easily liquefy in water, typical saline solution. But it is not steady in mixture state for long time, it must be changed within 24hours initial to use.

a. Physical Properties

The basic physical properties of Remifentanil are given in Table.3 shown below.

Table.3. Physical Properties of Remifentanil

Molecular Formula	$C_{20}H_{28}N_2O_5$
Molecular Weight	376.447 g/mol
pН	3
Density	$1.2 \pm 0.1 \text{g/cm}^3$
Boiling Point	487.8°C at 760
	mmHg
Vapour Pressure	1.22*10 ⁻⁸ mm Hg at
	25°C
Enthalpy of	75.4 ± 3.0 kJ / mol
Vaporization	
Volume of	350 mL/kg
distribution	452±144 mL/kg
	(infant)
	223±30.6 mL/kg
	(adults)

b. Pharmacodynamic Properties

Remifentanil is a clear μ effector protagonist whose sedative sensory-receptor pursuit has been explained in vitro. The drug characteristic of remifentanil is provoked by anodyne such as naloxone. The outcome of remifentanil is on the peripheral nervous system are mirror on the Electroencephalograph (EEG). By giving excessive dosage of remifentanil the process are decelerate the frequency and a rise in magnitude that changes reduces the spectral edge value[7]. These transpose are depends as the EEG impression on this drug. The breathing

dejection is nearly to the remifentanil blood accumulation and it has been utilized to calculate the drug effect for pharmacodynamics casting design [13]. It is dependent upon on the dosage level it reduces in pulse rate; venous blood pressure and rate of flow [14]. The undesirable effect incorporate retching, vomiting and muscle stiffness [7]. During surgery the consciousness has been associated with remifentanil drug level [17].

c. Pharmacokinetic Properties

Remifentanil is a poor base with a Pka of 7.07. In tag of the swiftness which congregation level reduces when injection dosage is terminated, remifentanil is extremely unlike from the further fentanyl congeneric. The chemical features accomplishing tremendously protein enclose stimulant, more or less 70% in which 2/3rd of binds to alpha-1-acid glycoprotein.

The importance of human total mass on remifentanil pharmacokinetic property is analyzed. This specifies that overweight sufferer should not gain a weight relative rise in amount of the drug given, by giving it may lead to crucial symptom such as hypotension and dysrhythmias. The spell needed to attain a body fluid at a constant rate of remifentanil by beginning an uninterrupted injection with any need of authority of doses in an around 15min [3]. In transgenesis studies with atracurium, mivaurium, esmolol, echothiophate and midazolam revealed no reluctance of remifentanil hydrolysis in total human blood by this type of drugs.

d. Dosage and Controlling

Remifentanil drug is controlled by in person particularly qualified in anesthetic. They must be well known about the maintenance and patient breathing flow rate. At constant insertion of remifentanil must be controlled by either attune injection gadget into impetuous IV line or via anexclusive IV line. The injection line should be joined to the tracheostomy cannula, to reduce the possible dead spot. It is firm for one day when it's kept below at 25°C after rearrangement and additionally concentration one of the below methods.

- > Fumigate water for inoculation.
- > 5% Dextrose inoculation.
- > 5% Dextrose and 0.9% sodium infusion.
- > 0.9% sodium chloride infusion.
- > 0.45% sodium chloride infusion.

e. Admissibility

Remifentanil drug is very well tolerated in ICU room with a mechanical external respiration. The frequently occurring negative impact of remifentanil receiver associate with to its μ -drugs protagonist characteristics. It is similar to the fentanyl or morphine used in ICU ward with a momentary mechanical external respiration for upto 3 days. There was no remarkable variation between remifentanil and fentanyl receiver in the occurrence of sickness, temperature or hyperpyrexia [5]. The generally side effects occur during remifentanil dosage is cardiac arrhythmia and vomiting. It is well suitable for pediatrics patient. In Fig.9 shows the peak time effect of Remifentanil with other type of drugs.




Fig.9. Comparison of Peak Effect Times of Remifentanil

f. Mechanism of Action

Remifentanil is a powerfull, artificial (man-made) drug that is replica of fentanyl. A 0.1mg dosage of remifentanil is almost equal to 10mg of fentanyl regulated by intravenous syringe. It triggers sensory organ nerves in the brain to raise the threshold to discomfort and diminish it. It also available in the form of transcutaneous and intramuscular form. Depth of Anaesthesia of Remifentanil drug in TIVA and TCI method are shown in below Fig.10.

Remifentanil (Ultiva)		
TIVA -	Anesthesia	TCI-dosage
dosage	Depth	
μg/ kg/ min		ng/ml
0.05	Drowsiness /	1.3
	Awake state	
0.10	Cymaamy	2.0
	Surgery	2.0
0.20	Anesthesia	3.0
	during surgery	
0.25	Suctioning	6.0
0.35	Strong pain	7.5
	stimulant	
0.50	Deep	10.0
0.30	Anesthesia	12.0
0.80	Very Deep	15.0
	Anesthesia	
Infusion		Target
Dose		Concentration

Fig. 10. DOA of Remifentanil

g. Excess Dosage level

In the happening of excess dosage:

- Desist managing
- > Continue watching the patient breathing
- ➤ It should be supervised with pure oxygen.
- > Important is to have a sufficient knowledge about cardiovascular working.

If miserable in breathing occurs with muscle inflexibility, neuromuscular blocking drug is vital to assist or controlled breathing. IV fluid and blood pressure are the for the therapy of hypotension and other type of sensitive measures are needed. The time span of breathing dysthymia followed by excess dosage is unexpected to the excess duration of the remifentanil drug induced to the patient. Excess dosage indication are an add on to the pharmaceutical inevitable measures of remifentanil. In Table.4 shows the basic characteristic of Remifentanil.

Characteristics	Artificial opioid analgesic (ultra short-acting); Supplement to		
	the anesthesia.		
Classification	Opioid agonists and antagonists		
Dosage level	Induction: 0.3-1 µg/kg		
	Sustentation of numbness: 0.1-1 µg/kg/ minute (by injection)		
	Drowsiness: injection rate $0.05 - 0.1 \mu g/kg/minute$		
Time span	5-10 minutes; conditions sympathetic half time 3 minutes		
Rejection time	Indiscriminate blood-tissue esterase's (small-organ		
	unconstrained)		
Drug Effects	Central Nervous system, Chorionic villus Sampling,		
	Respiratory, Gastrointestinal		
Advantage	Short-lasting of action, It can be back-pedal with naloxone drug		
Disadvantages	Nausea / vomiting, Chest wall rigidity		

Table.4. Characteristic of Remifentanil

VII. Interaction between Propofol and Remifentanil

During surgery patient accept sleep-inducing drug (eg. Propofol) to make sure to attain unconsciousness state. In furthermore the patient accepts an opioid dosage drug (eg. Remifentanil) to reduce the pain. In some of the cases the usage of Remifentanil drug is increased comparing with the mixture of Propofol. In the current usage of anesthesia are stated below.

- i) In ultra-modern drug delivery systems similar as TCI [8] it permit for an exact mixture and cautious controlling in patients with restricted treatment index;
- ii) In some of the cases, Remifentanils use as single drug for painfull surgery in patients breathing spontaneously.
- iii) Concurrently, Remifentanil has allowed has key in technical based research, which leads to the better understanding of rehabilitation of patient.

There are different types of models are used between injecting narcotics and painkiller have been explained [3]. Pharmacodynamic (PD) characteristics describe the interaction between two drugs concentration with their incorporate surgical drug reaction shown in exterior prototype.

The rate at which both remifentanil and propofol drug given to the patient during the operation are shown in the below Fig.11 detail.




Fig.11. Interaction between Remifentanil and Propofol drug during surgery

During the constant rate of anesthesia or drowsiness the amount of propofol control by decreasing with additional pain-relieving drug eg., nitrous oxide or any other types of opioid drug will not impact on regularly using non-depolarizing drug such as succinylcholine.

a. Advantage

- 1. The main aim of sedative drug given to the patient is attain by quick and with reduction in nontoxic.
- 2. It is used for speedy retrieval of patient is obtained by mixing of two drugs comparing to the single drug usage.

Table.5 Arterial Anesthetic Drug effect

Drug	Bolus dose	Infusion rate	Comments
Remifentanil	1 mg/kg	0.05 mg/kg/min	Hypoventilation, sickness, Vomiting, urinary infection
Propofol	2 – 2.5mg/kg	25-75 mg/kg/min	Venous infuriation, pain after injections

VIII. Conclusion

The reaction between Propofol and Remifentanil has its own characteristics in current anesthetic delivery system. If customized DOA monitoring system are anticipate, are depend upon the patient parameters. It can do by uniquely by instigate adaptation technique into feedback control method. At last it is finalized that remifentanil has narcotic / anodyne properties, or that it enhance the anodyne impact of propofol. Compared to the other types of drugs Propofol

and Remifentanil are fewer side effects. The recovery time is very less for these two drugs. It is easily available drug and commonly used in most of the surgery.

References.

- 1. Anonymous, "Remifentanil approved for anesthesia use", Am J Health System Pharm 53:1079-2082.
- 2. Anthony R.Absalon, Marko M. Sahinovic, et.all, "Clinical Pharmacokinetics and Pharmacodynamics of Propofol", Clin.Pharmacokinet, https://doi.org/10.1007/s40262-018-0672-3, 18 July2018.
- 3. Bharath Kumar.R, Suresh.P., "The Review Of Automation Anaesthesia For Medical Diagnosis In Biomedical Field", Turkish Journal Of Physiotherapy and Rehabilitation, 32(3); ISSN 2651-4451.
- 4. Bharath Kuamr.R, Suresh.P and Hemakumar.VS, "Automated Anesthesia Level Controller Using Fuzzy Logic for Injectable Type", Journal of Applied Science and Engineering, Vol.24, No.5, Pg. 749-755, http://dx.doi.org/10.6180/jase.202110_24(5).0009
- 5. Bharath Kumar.R, Suresh.P, Raja.P, Sivaperumal.S, International Journal system Assurance Engineering Management, Vol. 14, Pg. 486, https://doi.org/10.1007/s13198-021-01241-5.
- 6. Bouillon.T, Bruhn.J, and L.R., "Pharmacodynamics interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy, Anesthesiology, 100, 1353-1372, (2004).
- 7. Cafiero.T, F.Esposito, et.all, "Remifentanil-TCI and Propofol-TCI for conscious sedation during fiber optics intubation in the acromegalic patient", European Journal of Anaesthesiology 2008; 25: 670-674.
- 8. Copot.D, R.De Keyser, et.all, "Drug Interaction between Propofol and Remifentanil in Individualized Drug Delivery Systems", International Federation of Automatic Control, 48-20 (2015) 064-069.
- 9. Egan.T.D, Minto.C.F, et.all, "Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers, Anesthesiology 84: 821-833, 1996.
- 10. Egan.D.T, "The clinical pharmacology of remifentanil: a brief review", Journal of Anesthesia (1998)12:195-204.
- 11. Egan.T and Shafer.S, "Target-controlled infusions for intravenous anesthetics: surfing usa not!" Anesthesiology, 99, 1039-1041 (2003).
- 12. Gatlin.Larry Alan, Shirley Ann Heiman, and Janet Sue Lewis, "Stable Formulation of Remifentanil", U.S.Patent No 5, 866,591.2, Feb 1999.
- 13. Hassan Soleimanpour, "Propofol: An Update of its Use in Emergency Medicine", Emergency Med (Los Angel) Volume 6, Issue 3, 2016.
- 14. Kate McKeage and Caroline M. Perry, "Propofol A Review of its Intensive Care Sedation of Adults", CNS Drugs 2003; 17(4): 235-272.
- 15. Lemos.J.M and N.Cardoso, "Model Predictive Control of Depth of Anaesthesia: Guidelines for controller configuration", IEEE EMBS Conference, August 20-24, 2008.
- 16. Lifeng Zhang, Yang Bao, Dongping Shi, "Comparing the pain of propofol via different combinations of fentanyl, sufentanil or remifentanil in gastrointestinal endoscopy", Acta Cirurgica Brasileira-Vol.29 (10) 2014 -675.

- 17. Lysakowski.C, L.Dumont,et.all, "Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia", British Journal of Anaesthesia 86(4): 523-7,2001.
- 18. Manisha Bhatt, Saranjit Singh, et.all, "An Update on Clinical Concepts of Propofol", Journal of Evolution of Medical and Dental Sciences 2014; Vol.3, Issue 70, December 15; Page:14985-14992.
- 19. Marco A.Maurtua, Anupa Deogaonkar, et.all, "Dosing of Remifentanil to Prevent Movement During Craniotomy in the Absence of Neuromuscular Blockade", Journal of Neurosurgical Anesthesiology, Volume 20, Number 4, October 2008.
- 20. Minto.F.Charles, Thomas W.Schnider, et.all, "Influence of Age and Gender on the Pharmacokinetics and Pharmacodynamics of Remifentanil", Anesthesiology, V 86, No1, Jan1997.
- 21. Minto.F.Charles, Thomas W.Schnider, et.all, "Pharmacokinetics and Pharmacodynamics of Remifentanil", Anesthesiology, V 86, No1, Jan1997.
- 22. Moerman.A.T, L.A.Foubert,et.all, "Propofol versus remifentanil for monitored anaesthesia care during colonoscopy", European Journal of Anaesthesiology 2003; 20: 461-466.
- 23. Nandini.K, Mr.T.Surendran, Dr.S.Sobana, T.Kalaiselvi "Human Identification Using Contrast Enhanced Segmented Palm-Vein Images", IOP Conf. Series: Materials Science and Engineering et al 2020 IOP Conf. Ser.: Mater. Sci. Eng. 993 012097.
- 24. Scott.H.B, S.W.Choi,et.all, "The effect of remifentanil on propofol requirements to achieve loss of response to command vs. loss of response to pain", Anaesthesia 2017, 72, 479-487.
- 25. Shahab Anna and Peng Wen, "Depth of Anesthesia Control using Internal Model Control Techniques", University of Southern Queensland, February 11, 2010.
- 26. Steven L.Shafer, M.D., Dennis M. Fisher, M.D., "Remifentanil Dosing at Extremes of Body weight", the American Society of Anesthesiologists, Anesthesiology 2017; 126: 993-4.
- 27. Toshiya Koitabashi, Jay W.Johansen, et.all, "Remifentanil Dose/ Electroencephalogram Bispectral Response During Combined Propofol / Regional Anaesthesia", International Anesthesia Research Society, Anesth Analg 2002; 94:1530-3.
- 28. Van den Berg.J.P, H.E.M. Vereecke, et.all, "Pharmacokinetic and Pharmacodynamics interactions in anaesthesia. A review of current knowledge and how it can be used to optimize anaesthetic drug administration", British Journal of Anaesthesia, 118(1): 44-57 (2017).
- 29. White.F.Paul, "Propofol Its Role in changing the practice of Anesthesia", Anesthesiology 2008; 109: 1132-6.
- 30. Yufune.S, I.Takamatsu, et.all, "Effect of remifentanil on plasma propofol concentration and bispectral index during propofol anesthesia", British Journal of Anaesthesia 106(2): 208-14 (2011).
- 31. DIPRIVAN® (Propofol) injectable emulsion, USP, 45109H/ Revised: April 2017.
- 32. Ultiva® for Injection (remifentanil hydrochloride), NDA 20-630/S-005, 2001.
- 33. www.druginfo.adf.org.au